U.S. Online Retail and Ecommerce Stock News

NYSE:DTE
NYSE:DTEIntegrated Utilities

A Look At DTE Energy (DTE) Valuation After Solid Annual Results And Confirmed EPS Guidance

DTE Energy earnings results and guidance in focus DTE Energy (DTE) has drawn fresh attention after reporting full year 2025 results, with revenue and net income figures updated, and confirming 2026 operating EPS guidance in the US$7.59 to US$7.73 range. See our latest analysis for DTE Energy. Against this backdrop of full year 2025 results and confirmed 2026 EPS guidance, DTE Energy’s 1 month share price return of 8.58% and year to date share price return of 11.88% suggest momentum has been...
NYSE:QBTS
NYSE:QBTSSoftware

Is D-Wave Quantum (QBTS) Using the Southeastern Consortium to Quietly Recast Its Competitive Moat?

In February 2026, D-Wave Quantum Inc. joined the newly formed Southeastern Quantum Collaborative as an inaugural member, partnering with regional universities, IBM, Davidson Technologies, and Alabama A&M University to advance quantum information science and workforce development across the U.S. Southeast. By tying its Advantage2 system hosted at Davidson’s Huntsville facility into this consortium, D-Wave gains a practical channel to embed its technology in real-world defense and industrial...
NasdaqGS:ZYME
NasdaqGS:ZYMEBiotechs

How Positive Zanidatamab Phase 3 Data And Buyback Plans At Zymeworks (ZYME) Have Changed Its Investment Story

Zymeworks recently reported positive Phase 3 results for zanidatamab in first-line HER2-positive gastroesophageal cancer, alongside year-end 2025 financials showing solid cash reserves and an existing US$125 million share repurchase authorization, while Redmile Group disclosed about US$70 million of share sales. Together, the encouraging late-stage clinical data, strengthened balance sheet, and ongoing buyback authorization highlight a shift toward reinforcing the company’s royalty-focused,...
NYSE:CAVA
NYSE:CAVAHospitality

CAVA Group (CAVA) Is Up 7.6% After Tariff Jitters Meet Earnings Miss - What's Changed

CAVA Group recently faced renewed uncertainty as newly announced global tariffs disrupted sentiment around internationally exposed supply chains, coinciding with the company’s latest earnings miss against consensus expectations. This combination of trade policy risk and a closely watched earnings backdrop has sharpened investor focus on how resilient CAVA’s growth and margin ambitions may be under shifting cost and demand conditions. We’ll now examine how heightened tariff uncertainty...
NYSE:RACE
NYSE:RACEAuto

Ferrari Launches €3.5b Buyback As Valuation And Momentum Diverge

Ferrari (NYSE:RACE) has launched a multi year share buyback program totaling €3.5b. The company has started the first tranche of purchases, beginning the execution phase of this plan. The buyback framework is designed to run over several years, signaling active capital return to shareholders. For investors, this move comes from a company known for its high end sports cars, racing heritage, and tightly controlled brand. A multi year buyback of this size reflects a balance sheet that can...
NYSE:MSGS
NYSE:MSGSEntertainment

A Look At Madison Square Garden Sports (MSGS) Valuation After Recent Share Price Pullback

Recent performance snapshot Madison Square Garden Sports (MSGS) has drawn fresh attention after a recent pullback, with the stock down about 3.4% over the past day but still positive over the past week and month. See our latest analysis for Madison Square Garden Sports. The recent 3.4% one day share price pullback to US$314.09 comes after a strong run, with a 90 day share price return of 39.7% and a 1 year total shareholder return of 55%. This suggests momentum has been strong even as short...
NYSE:LC
NYSE:LCConsumer Finance

Assessing LendingClub (LC) Valuation As Revenue And Earnings Growth Draw Fresh Investor Focus

LendingClub event puts recent fundamentals in focus Recent data on LendingClub (LC) is drawing fresh attention, with annual revenue growth of 25.7% and earnings per share rising 79.1% each year. These figures are prompting investors to reassess the online lender’s fundamentals. See our latest analysis for LendingClub. The recent 1 month share price return of 29.93% decline and year to date share price return of 22.86% decline contrast with a 1 year total shareholder return of 18.28%. This...
NYSE:UDR
NYSE:UDRResidential REITs

UDR Shelf Registration Adds Funding Flexibility To Valued Residential REIT

UDR, Inc. (NYSE:UDR) has filed an omnibus shelf registration, allowing it to issue common stock, preferred stock, debt securities, and other instruments. The filing gives the company the option to raise capital as needed, without having to complete a separate registration for each issuance. UDR, Inc. comes into this filing with its shares at $37.37 and a mixed return profile, including a 7.6% gain over the past 5 years and a 9.5% decline over the past year. For you as an investor, the shelf...
NYSE:ZWS
NYSE:ZWSBuilding

A Look At Zurn Elkay Water Solutions (ZWS) Valuation After Strong Multi Year Returns

What Zurn Elkay Water Solutions’ Recent Performance Signals for Investors Zurn Elkay Water Solutions (ZWS) has drawn fresh attention after a period of mixed short term returns, with the stock showing a 1 day decline, a small weekly pullback, yet gains over the past month and past 3 months. At a last close of US$49.93, the company sits on a 1 year total return of 44.56%. Longer horizons show very large gains over 3 and 5 years, alongside annual revenue of US$1.70b and net income of...
NasdaqGS:LYFT
NasdaqGS:LYFTTransportation

What Lyft (LYFT)'s Profitable 2025 and New US$1 Billion Buyback Mean For Shareholders

Earlier in February 2026, Lyft reported full-year 2025 results showing US$6,316.26 million in sales and US$2,844.01 million in net income, alongside a new US$1,000 million share repurchase authorization and a US$337.72 million employee stock-related shelf registration for Class A common stock. These moves, combined with management’s focus on market share recovery, pricing discipline and operational efficiencies, highlight Lyft’s effort to balance employee incentives, capital returns and...
NasdaqGS:IRTC
NasdaqGS:IRTCMedical Equipment

How iRhythm’s Profit Return and 2026 Outlook Could Reshape the Story for iRhythm Holdings (IRTC) Investors

In February 2026, iRhythm Holdings reported Q4 2025 results showing sales of US$208.89 million and a return to quarterly profitability, while full-year 2025 revenue reached US$747.14 million with a reduced annual net loss. The company also issued 2026 revenue guidance of US$870 million to US$880 million and highlighted expansion plans, AI-enabled product development, and international growth initiatives as it works to improve efficiency and broaden its cardiac monitoring platform. We’ll now...
NYSE:YOU
NYSE:YOUSoftware

Clear Secure Tests Healthcare Growth Story With Mount Sinai CLEAR1 Rollout

Clear Secure (NYSE:YOU) announced a collaboration with Mount Sinai Health System to roll out its CLEAR1 digital identity platform across the New York City based healthcare network. The agreement focuses on improving identity verification and check in for both patients and employees within one of the region's largest academic medical systems. Clear Secure, trading at $32.73, is best known for its airport security lanes, but this move signals a push into healthcare identity services. The...
NYSE:CNC
NYSE:CNCHealthcare

Is Centene’s (CNC) AI-Driven Transport And Community Spend Redefining Its Medicaid Moat?

In recent years, Centene’s Health Net unit invested more than US$284 million in California community programs to expand access to medical, behavioral, nutritional, and supportive services for Medi-Cal members, while the company has also been adopting AI-powered healthcare transportation technologies. These efforts to improve whole-person care, reduce health disparities, and enhance medical transport efficiency highlight how Centene is tying technology and community investment to its core...
NYSE:GPC
NYSE:GPCRetail Distributors

Genuine Parts Split Plan Raises Questions On Value And Future Returns

Genuine Parts plans to separate into two independent, tax free companies by Q1 2027. The split will create a dedicated Global Automotive business and a separate Global Industrial business. The company expects the separation to sharpen business focus and reshape its long term direction. For NYSE:GPC shareholders, this planned breakup comes after a challenging stretch for the stock. Shares are at $116.16, with a 21.1% decline over the past week and a 15.6% decline over the past month. Over 3...
NYSE:HHH
NYSE:HHHReal Estate

Howard Hughes Holdings Blends Real Estate And Insurance As Valuation Lags

Howard Hughes Holdings (NYSE:HHH) is shifting its business model by acquiring specialty insurer Vantage Group Holdings Ltd. The company plans to reposition itself as a diversified holding company that includes both real estate and insurance operations. Recent operational updates include the opening of the Teravalis community and record results from its Master Planned Communities segment. Howard Hughes Holdings, trading around $72.62, is in the middle of a broad repositioning that extends...
NYSE:MO
NYSE:MOTobacco

Assessing Altria (MO) Valuation After Renewed Analyst Optimism Post CAGNY Conference

Recent analyst commentary around Altria Group (MO) has picked up after the company highlighted industry efforts against illicit trade at the CAGNY conference, prompting fresh views on its cash generation, margins, and smoke free product shift. See our latest analysis for Altria Group. The recent uplift in analyst attention has arrived alongside stronger momentum in Altria Group’s shares, with a 30 day share price return of 11.42% and a year to date share price return of 20.36%, while the 1...
NasdaqGS:INDB
NasdaqGS:INDBBanks

Independent Bank (INDB) Valuation Check After Recent Pullback And Premium P/E Multiple

Independent Bank stock moves after recent performance shift Independent Bank (INDB) has drawn fresh attention after a recent pullback, with the stock down about 4% over the past week and 4% over the past day, despite gains over the past 3 months. See our latest analysis for Independent Bank. That pullback sits against a stronger backdrop, with a 90 day share price return of 8.46% and a 1 year total shareholder return of 22.18%, suggesting momentum has cooled recently after a steadier...
NasdaqGS:ALNY
NasdaqGS:ALNYBiotechs

Will Alnylam’s (ALNY) 2025 Profitability and $2.26 Billion Shelf Filing Redefine Its Risk Profile?

Alnylam Pharmaceuticals reported fourth-quarter 2025 revenue of US$1,097.03 million and net income of US$111.54 million, with full-year 2025 revenue of US$3.71 billion and net income of US$313.75 million, alongside filing a US$2.26 billion shelf registration for 7,000,000 common shares under an ESOP-related offering. This shift from prior-year losses to earnings, paired with preparations for potential equity issuance, highlights a company transitioning financially while planning for future...
NYSE:NEE
NYSE:NEEElectric Utilities

Should NextEra’s Dividend Hike and Data Center Push Reframe How NEE Investors View Its Growth Engine?

Earlier in February 2026, NextEra Energy, Inc. declared a regular quarterly dividend of US$0.6232 per share, a 10% increase on the prior-year comparable payout, as part of its plan for roughly 10% annual dividend per-share growth through 2026 and 6% per year from 2027 to 2028. This higher dividend, alongside management’s longer-term earnings growth ambitions and expanding data center power partnerships, highlights how the company is tying shareholder returns to rising electricity...
NasdaqGS:COLL
NasdaqGS:COLLPharmaceuticals

Is Collegium Pharmaceutical (COLL) Pricing Look Attractive After Strong Multi‑Year Share Gains?

If you are wondering whether Collegium Pharmaceutical at around US$44.85 is good value or looking fully priced, the key is understanding how its current share price stacks up against a few different valuation checks. The stock has had a mixed run recently, with a 2.1% decline over the last 7 days and a 1.4% decline over the last 30 days, even though the 1 year return sits at 53.6% and the 3 year return at 67.4%. Recent attention on Collegium has focused on its position within the US...
NasdaqGS:PRAX
NasdaqGS:PRAXBiotechs

Assessing Praxis Precision Medicines (PRAX) Valuation After Strong Recent Share Price Momentum

Stock moves and recent performance context Praxis Precision Medicines (PRAX) has drawn fresh attention after recent share price moves. The stock closed at US$342.46 and posted a one-month return of 9.9% and a three-month return of 85.9%. See our latest analysis for Praxis Precision Medicines. Beyond the recent bounce, Praxis Precision Medicines has paired strong short term share price momentum with very large one year and multi year total shareholder returns. This combination suggests...
NYSE:ADM
NYSE:ADMFood

Did SEC Fraud Charges and Governance Concerns Just Shift Archer-Daniels-Midland's (ADM) Investment Narrative?

Recently, the SEC charged Archer-Daniels-Midland and three former executives with accounting and disclosure fraud, alleging improper revenue recognition and misleading financial statements that misinformed investors. This enforcement action raises fresh questions about ADM’s internal controls and governance culture at a time when the company is already facing operational and margin pressures. We’ll now examine how these SEC fraud charges, and the governance concerns they raise, could...
NYSE:BRO
NYSE:BROInsurance

Brown And Brown Taps New CIO To Shape AI And Technology Path

Brown & Brown (NYSE:BRO) has appointed Dorothea “Dori” Henderson as Chief Information Technology Officer. Henderson will lead the company’s technology and AI agenda, with a focus on digital transformation and enterprise systems. Brown & Brown, trading at $69.16, is putting more attention on its technology direction at a time when digital capabilities are central to how insurance distributors operate. The stock shows mixed performance, with a 26.1% return over 3 years and 52.7% over 5 years,...
NasdaqGM:ALVO
NasdaqGM:ALVOBiotechs

Alvotech (ALVO) Is Down 9.1% After FDA Rejects AVT05 Over Facility Issues and Legal Probe

In the past few days, law firm Kirby McInerney LLP announced it is investigating Alvotech and certain executives for potential federal securities law violations after the FDA issued a complete response letter citing a failed facility inspection for its AVT05 biologics license application. This combination of regulatory setback and investor scrutiny raises fresh questions about Alvotech’s quality controls, regulatory risk management, and disclosure practices around its biosimilar...